| abstract |
Compounds of Formula 1, stereoisomers of these, and pharmaceutically acceptable salts thereof are described, where L, r, s, R5, R6, R7, R9, R10, R11, R12, X1, X2, X3, X4, X13, and X14 are defined in the specification. This description also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions containing them, and to their use to treat diseases, disorders and conditions associated with SSTR4. |